SPR Therapeutics

Executive Summary

SPR Therapeutics is a private medical device company based in Cleveland, Ohio, dedicated to developing and commercializing minimally invasive peripheral nerve stimulation (PNS) systems for chronic pain management. Founded in 2009, the company's flagship SPRINT® PNS System is a temporary, 60-day treatment that has received FDA clearance, offering a drug-free, non-opioid alternative for patients suffering from various chronic pain conditions. The technology targets the peripheral nervous system to provide pain relief without the need for implants or ongoing stimulation, differentiating it from traditional spinal cord stimulation and opioid-based therapies. With an aging population and increasing focus on non-opioid pain management, SPR Therapeutics is positioned to capture significant market share, though as a private company it faces challenges in scaling clinical evidence and securing commercial partnerships. The company has a strong intellectual property portfolio and is likely pursuing additional FDA clearances for broader indications.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for new chronic pain indication (e.g., post-surgical or neuropathic pain)70% success
• Q2 2027Announcement of strategic partnership or distribution agreement with a larger medical device company50% success
• Q1 2027Publication of pivotal clinical trial results demonstrating superiority over standard of care60% success